About Semaglutide
Class: GLP-1 RA
Brand/Manufacturer: Generic
Dosing: Weekly subcutaneous
Mean weight loss: 14.9%
Pivotal trial: STEP-1, NEJM 2021
Semaglutide is a GLP-1 receptor agonist (GLP-1 RA) used for type 2 diabetes (Ozempic, Rybelsus) and chronic weight management (Wegovy). Compounded semaglutide is dispensed by 503A and 503B pharmacies via telehealth. Mean weight loss in STEP-1 was 14.9% at 68 weeks. Cardiovascular outcome benefit established in SUSTAIN-6 (T2D) and SELECT (overweight/obese without diabetes).
Mechanism of action
Semaglutide acts on the GLP-1 receptor (and GIP receptor in the case of tirzepatide), producing four primary effects: central appetite suppression, delayed gastric emptying, glucose-dependent insulin release, and glucagon suppression. The combined effect on body weight averaged across pivotal trials is 14.9% body weight reduction at the trial endpoint.
Clinical evidence
The pivotal trial supporting Semaglutide's weight management indication is STEP-1, NEJM 2021. Detailed data including primary and secondary endpoints, population characteristics, and adverse event frequencies is summarized on our clinical research page.
How to access Semaglutide via telehealth
Semaglutide is available through several U.S. telehealth providers. Compounded versions (where applicable) are dispensed by 503A licensed compounding pharmacies and 503B FDA-registered outsourcing facilities. NexLife is our editorial #1 pick for Semaglutide access — see the side panel for details.
FAQ
Is Semaglutide FDA-approved?
The brand-name versions of Semaglutide are FDA-approved for the indications listed above. Compounded versions are not FDA-approved.
How much does Semaglutide cost?
Brand-name Semaglutide typically costs hundreds to over a thousand dollars per month at retail. Compounded equivalents (where available) cost significantly less. See our cost guide for verified May 2026 pricing.